LONDON (Reuters) - GlaxoSmithKline has completed its $3 billion acquisition of long-time biotech partner Human Genome Sciences, after buying all the outstanding shares for $14.25 each in cash, Britain's biggest drugmaker said on Friday.

The deal secures it full rights to recently launched lupus drug Benlysta and other experimental medicines.

(Reporting by Ben Hirschler)